The gathering of global public health experts identified the following as the primary barriers to the use of magnesium sulfate:
• Lack of National Priority and Guidelines. In countries like Nigeria, Uganda, and Pakistan, guidelines mandating magnesium sulfate use do not exist, and only about half of the world’s countries include magnesium sulfate on their national list of “essential drugs.”
• Lack of Education and Training. Many clinicians remain unfamiliar with the safety and effectiveness of magnesium sulfate and continue to rely on other, less-effective and riskier drugs.
• Supply Shortage. Relative to other health conditions, pre-eclampsia and eclampsia affect a small population. In addition, magnesium sulfate is relatively inexpensive. In combination, these factors leave little or no incentive for pharmaceutical companies to make magnesium sulfate more widely available.
Based on these conclusions, EngenderHealth and the University of Oxford have developed a “Call to Action” that calls on policy makers and ministers of health to make pre-eclampsia and eclampsia a higher priority and to set national guidelines for treatment and care based on WHO guidelines. It also urges decision makers and international and national health organizations and agencies to help make magnesium sulfate more available and affordable, in part by empowering local clinicians with education and training.
"Today, magnesium sulphate is still not available in the hospitals of many countries, nor is it on the countries' essential drug lists," the group said.
Source-Medindia
GPL/V